<DOC>
	<DOCNO>NCT01743937</DOCNO>
	<brief_summary>Antiplatelet therapy remain cornerstone treatment acute chronic coronary artery disease . Aspirin first therapy prove benefit acute myocardial infarction . Compared aspirin monotherapy , combination aspirin clopidogrel , thienopyridine P2Y12 inhibitor , demonstrate reduce adverse event rate among patient acute coronary syndrome ( without ST-segment elevation ) receive intracoronary stent . In Triton-TIMI 38 trial novel thienopyridine , prasugrel , compare clopidogrel patient acute coronary syndrome undergo percutaneous coronary intervention . Although prasugrel significantly reduce recurrent myocardial infarction , bleed rate increase improvement cardiac all-cause mortality demonstrate . However , 2009 , author PLATO trial demonstrate unexpected cardiovascular mortality benefit ticagrelor clopidogrel , endpoint previously meet antiplatelet agent active comparator . Based reproducible adverse event see DISPERSE , DISPERSE-2 , PLATO trial , adenosine-mediated effect ticagrelor propose . Hypothesis : The aim study test hypothesis ticagrelor produce pharmacologic ischemic preconditioning , undescribed potential off-label property ticagrelor could represent plausible mechanism effect cardiovascular mortality .</brief_summary>
	<brief_title>A Trial Comparing Ischemic Preconditioning Effects Ticagrelor Clopidogrel Humans</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Undergoing clinicallyindicated PCI stable progressive exertional angina without rest angina , STsegment shift , elevate CKMB troponinT I Willing able give inform consent comply study procedure Found single twovessel obstructive , nonocclusive ( ≥ 70 % &lt; 100 % stenosis ) , coronary artery disease plan treatment lesion PCI Target lesion location proximal mid coronary vessel reference diameter ≥ 2.5 mm Known allergy aspirin , clopidogrel , ticagrelor Need concomitant cardiac procedure , valve repair replacement Age ≥ 75 Concomitant theophylline/aminophylline use Baseline ECG infarct conduction abnormality ( i.e . LVH repolarization abnormality , bundle branch block , STsegment abnormality ) Presenting STsegment elevation non STsegment elevation myocardial infarction Evidence prior myocardial infarction cardiac imaging Depressed leave ventricular systolic function ( ejection fraction &lt; 50 % ) Clinical congestive heart failure Endstage renal disease Presence coronary collateral diagnostic coronary angiography Presence coronary thrombus diagnostic coronary angiography Diffuse obstructive disease ( ≥ 70 % stenosis ) distal segment target vessel Left main and/or threevessel coronary artery disease Concomitant need Warfarin therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Ischemic preconditioning</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>Acute coronary syndrome</keyword>
</DOC>